What is the clinical evidence from this study?

Study design: Observational. Population: Breast cancer. Primary outcome: Age-adjusted mortality rates (AAMRs) per 100,000 population for arrhythmia-associated mortality.

What does this research mean for the field?

Arrhythmia-associated mortality is a substantial and persistent burden among breast cancer patients, particularly affecting older individuals, White populations, and those residing in metropolitan areas. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This study aims to assess the impact of arrhythmias on mortality among adults with breast cancer in the U.S.

May 30, 2026

Cardiomyopathy mortality among U.S. adults with breast cancer: A 25-year CDC WONDER study.

Key Result

Arrhythmia-associated mortality among U.S. adults with breast cancer remained a persistent burden over a 25-year period, with the highest age-adjusted mortality rates in individuals aged ≥65 years.

Key Points

This study aims to assess the impact of arrhythmias on mortality among adults with breast cancer in the U.S.
Retrospective population-based study using CDC WONDER death certificate data.
Identified deaths with breast cancer as the underlying cause and arrhythmias as contributing causes.
Calculated age-adjusted mortality rates using the 2000 U.S. standard population, stratifying by age, sex, race/ethnicity, and urbanization.
Arrhythmia-associated mortality showed an increase with age, notably among individuals ≥65 years.
White decedents exhibited higher absolute age-adjusted mortality rates compared to other racial groups.
Mortality rates were elevated in metropolitan areas, indicating geographic disparities.

Study Design

Type

Observational

Multicenter

Yes

Structured PICO

Population

U.S. adults with breast cancer (ICD-10 C50) as the underlying cause of death and arrhythmias (ICD-10 I47–I49) as contributing causes

Outcome

Age-adjusted mortality rates (AAMRs) for arrhythmia-associated mortalityhard clinical

Arrhythmias are a significant and persistent contributor to mortality among patients with breast cancer, highlighting the need for integrated cardio-oncology strategies.

Abstract

e13139 Background: Cardiovascular disease is an increasingly recognized contributor to mortality among cancer patients. Arrhythmias may represent an underappreciated cause of death in breast cancer, particularly among older individuals and those receiving cardiotoxic therapies. We examined national multiple cause of death data to characterize the burden and demographic patterns of arrhythmia-associated mortality in breast cancer. Methods: This retrospective population-based study used CDC WONDER death certificate data. Deaths with breast cancer (ICD-10 C50) as the underlying cause and arrhythmias (ICD-10 I47–I49) as contributing causes were identified. Age-adjusted mortality rates (AAMRs) per 100,000 population were calculated using the 2000 U.S. standard population. Analyses followed STROBE guidelines and were stratified by age, sex, race/ethnicity, and urbanization. Temporal trends were evaluated descriptively using AAMRs with 95% confidence intervals. Results: Arrhythmia-associated mortality in breast cancer patients remained substantial throughout the study period. AAMRs increased with advancing age, with the highest rates among individuals aged ≥65 years. Racial disparities were observed, with White decedents showing higher absolute AAMRs compared with other groups. Although breast cancer predominantly affects women, sex-stratified analyses showed a notable burden of arrhythmia-related mortality. Mortality rates were higher in metropolitan areas compared with non-metropolitan regions. Temporal analyses indicated persistent arrhythmia-associated mortality over the study period. Conclusions: Arrhythmias are a significant and persistent contributor to mortality among patients with breast cancer. The age-related increase and observed demographic disparities highlight the importance of cardiovascular risk assessment and arrhythmia monitoring in this population. These findings support the integration of cardio-oncology strategies to reduce non-cancer mortality among patients with breast cancer.

AIに質問

Bookmark